We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A Moderna or Pfizer/BioNTech COVID-19 booster dose was found to give highly effective protection against the Delta and Omicron variants, the Centers of Disease Control and Prevention (CDC) said Friday. Read More
The FDA has placed clinical holds on two drugs that use the transferrin receptor to gain access to their sites of action, raising concerns about the entire approach. Read More
As the Omicron variant rages, Peter Marks, the FDA’s top vaccine regulator, said that getting a booster dose earlier than six months after initial doses may be the best way to guard against the ubiquitous variant. Read More
In June 2021, the FDA approved Pfizer’s Prevnar 20 jab for preventing invasive disease and pneumonia from 20 different strains of streptococcus. Read More
AstraZeneca has signed a collaboration deal with Scorpion Therapeutics to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, the so-called “undruggable” targets. Read More
Sanofi has agreed to buy exclusive global rights to develop Korean company ABL Bio’s preclinical antibody for the treatment of neurodegenerative conditions, including Parkinson’s disease. Purchase price: $75 million upfront, with additional payments that could total $1 billion. Read More
Amgen and Arrakis Therapeutics have teamed up to develop targeted RNA degraders, an entirely new class of therapeutic molecules designed to destroy disease-causing RNA. Read More
Results seen across multiple trials bolster Sarepta’s “confidence in the potential disease-modifying benefits of this therapy,” said the company’s CEO, Doug Ingram. Read More
BioMarin plans to meet with the FDA to discuss these latest findings and expects to file a biologics license application in the second quarter of this year. Read More